Total Payments
$47,064
2024 Payments
$350.00
Companies
11
Transactions
36
Medicare Patients
835
Medicare Billing
$108,176
Payment Breakdown by Category
Consulting$25,523 (54.2%)
Travel$10,203 (21.7%)
Other$10,054 (21.4%)
Food & Beverage$1,271 (2.7%)
Education$11.92 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $25,523 | 6 | 54.2% |
| Travel and Lodging | $10,203 | 8 | 21.7% |
| Honoraria | $9,704 | 1 | 20.6% |
| Food and Beverage | $1,271 | 19 | 2.7% |
| Grant | $350.00 | 1 | 0.7% |
| Education | $11.92 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $31,892 | 25 | $0 (2022) |
| Chiesi USA, Inc. | $14,054 | 2 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $350.00 | 1 | $0 (2024) |
| Incyte Corporation | $335.00 | 1 | $0 (2017) |
| TESARO, Inc. | $123.87 | 1 | $0 (2018) |
| Bayer HealthCare Pharmaceuticals Inc. | $83.88 | 1 | $0 (2018) |
| AbbVie, Inc. | $64.31 | 1 | $0 (2018) |
| Genentech USA, Inc. | $63.39 | 1 | $0 (2017) |
| Puma Biotechnology, Inc. | $50.20 | 1 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $34.99 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $350.00 | 1 | AstraZeneca Pharmaceuticals LP ($350.00) |
| 2023 | $9,755 | 2 | Chiesi USA, Inc. ($9,704) |
| 2022 | $3,039 | 3 | GENZYME CORPORATION ($3,039) |
| 2021 | $4,362 | 2 | Chiesi USA, Inc. ($4,350) |
| 2020 | $1,684 | 1 | GENZYME CORPORATION ($1,684) |
| 2019 | $20,056 | 10 | GENZYME CORPORATION ($20,056) |
| 2018 | $1,607 | 13 | GENZYME CORPORATION ($1,300) |
| 2017 | $6,211 | 4 | GENZYME CORPORATION ($5,813) |
All Payment Transactions
36 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/14/2024 | AstraZeneca Pharmaceuticals LP | — | Grant | Cash or cash equivalent | $350.00 | General |
| 11/16/2023 | Chiesi USA, Inc. | ELFABRIO (Drug) | Honoraria | Cash or cash equivalent | $9,704.35 | General |
| Category: ERT FOR FABRY DISEASE | ||||||
| 02/16/2023 | Puma Biotechnology, Inc. | — | Food and Beverage | In-kind items and services | $50.20 | General |
| 10/19/2022 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $91.04 | General |
| 04/28/2022 | GENZYME CORPORATION | FABRAZYME (Biological) | Consulting Fee | Cash or cash equivalent | $2,884.00 | General |
| Category: Genetic Disease | ||||||
| 02/09/2022 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $64.07 | General |
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 02/03/2021 | Chiesi USA, Inc. | FERRIPROX (Drug) | Consulting Fee | Cash or cash equivalent | $4,350.00 | General |
| Category: HEMATOLOGY, DISEASE | ||||||
| 10/07/2020 | GENZYME CORPORATION | CERDELGA (Drug) | Consulting Fee | Cash or cash equivalent | $1,684.00 | General |
| Category: Genetic Disease | ||||||
| 10/11/2019 | GENZYME CORPORATION | CERDELGA (Drug) | Food and Beverage | In-kind items and services | $51.83 | General |
| Category: RARE DISEASE GENETICS | ||||||
| 10/10/2019 | GENZYME CORPORATION | CERDELGA (Drug) | Consulting Fee | Cash or cash equivalent | $10,478.00 | General |
| Category: RARE DISEASE GENETICS | ||||||
| 10/10/2019 | GENZYME CORPORATION | CERDELGA (Drug) | Travel and Lodging | In-kind items and services | $8,832.43 | General |
| Category: RARE DISEASE GENETICS | ||||||
| 10/10/2019 | GENZYME CORPORATION | CERDELGA (Drug) | Travel and Lodging | In-kind items and services | $437.31 | General |
| Category: RARE DISEASE GENETICS | ||||||
| 10/10/2019 | GENZYME CORPORATION | CERDELGA (Drug) | Travel and Lodging | Cash or cash equivalent | $65.13 | General |
| Category: RARE DISEASE GENETICS | ||||||
| 10/10/2019 | GENZYME CORPORATION | CERDELGA (Drug) | Travel and Lodging | In-kind items and services | $58.31 | General |
| Category: RARE DISEASE GENETICS | ||||||
| 10/10/2019 | GENZYME CORPORATION | CERDELGA (Drug) | Travel and Lodging | Cash or cash equivalent | $54.00 | General |
| Category: RARE DISEASE GENETICS | ||||||
| 10/10/2019 | GENZYME CORPORATION | CERDELGA (Drug) | Food and Beverage | In-kind items and services | $42.61 | General |
| Category: RARE DISEASE GENETICS | ||||||
| 10/10/2019 | GENZYME CORPORATION | CERDELGA (Drug) | Food and Beverage | In-kind items and services | $28.33 | General |
| Category: RARE DISEASE GENETICS | ||||||
| 10/10/2019 | GENZYME CORPORATION | CERDELGA (Drug) | Food and Beverage | In-kind items and services | $7.92 | General |
| Category: RARE DISEASE GENETICS | ||||||
| 08/14/2018 | TESARO, Inc. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $123.87 | General |
| Category: ONCOLOGY | ||||||
| 08/14/2018 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $34.99 | General |
| Category: ONCOLOGY | ||||||
| 08/13/2018 | Bayer HealthCare Pharmaceuticals Inc. | Aliqopa (Drug) | Food and Beverage | In-kind items and services | $83.88 | General |
| Category: Oncology | ||||||
| 08/12/2018 | AbbVie, Inc. | Venclexta (Drug) | Food and Beverage | In-kind items and services | $64.31 | General |
| Category: Virology | ||||||
| 05/10/2018 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | In-kind items and services | $524.70 | General |
| 05/10/2018 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | In-kind items and services | $213.57 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 277 | 348 | $161,709 | $32,419 |
| 2022 | 6 | 196 | 291 | $135,312 | $27,573 |
| 2021 | 7 | 201 | 298 | $123,431 | $27,805 |
| 2020 | 6 | 161 | 252 | $93,072 | $20,378 |
Total Patients
835
Total Services
1,189
Medicare Billing
$108,176
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 81 | 118 | $54,062 | $10,846 | 20.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 37 | 37 | $29,517 | $6,101 | 20.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 90 | 97 | $31,561 | $5,450 | 17.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 28 | 32 | $20,727 | $4,456 | 21.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 15 | 38 | $10,836 | $2,390 | 22.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 14 | 14 | $9,222 | $1,930 | 20.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 12 | 12 | $5,784 | $1,245 | 21.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 73 | 124 | $56,722 | $11,421 | 20.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 61 | 74 | $23,928 | $4,695 | 19.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 27 | 27 | $21,411 | $4,336 | 20.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 11 | 36 | $13,143 | $2,903 | 22.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 13 | 18 | $11,600 | $2,339 | 20.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 12 | $8,508 | $1,879 | 22.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 56 | 106 | $43,960 | $10,076 | 22.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 62 | 69 | $20,490 | $4,619 | 22.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 17 | 52 | $19,140 | $4,312 | 22.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 19 | 19 | $13,578 | $3,057 | 22.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 16 | 20 | $11,694 | $2,490 | 21.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 13 | 13 | $9,699 | $2,162 | 22.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 18 | 19 | $4,870 | $1,089 | 22.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 16 | 61 | $22,258 | $5,181 | 23.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 65 | 86 | $22,092 | $4,383 | 19.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 23 | 24 | $16,987 | $3,962 | 23.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 29 | 51 | $18,951 | $3,879 | 20.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 11 | 11 | $7,944 | $1,849 | 23.3% |
About Dr. Coy Heldermon, MD
Dr. Coy Heldermon, MD is a Medical Oncology healthcare provider based in Gainesville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1467474502.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Coy Heldermon, MD has received a total of $47,064 in payments from pharmaceutical and medical device companies, with $350.00 received in 2024. These payments were reported across 36 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($25,523).
As a Medicare-enrolled provider, Heldermon has provided services to 835 Medicare beneficiaries, totaling 1,189 services with total Medicare billing of $108,176. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Medical Oncology
- Location Gainesville, FL
- Active Since 07/25/2006
- Last Updated 11/18/2009
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1467474502
Products in Payments
- CERDELGA (Drug) $27,532
- ELFABRIO (Drug) $9,704
- FERRIPROX (Drug) $4,350
- FABRAZYME (Biological) $2,884
- NO PRODUCT DISCUSSED (Drug) $1,230
- ZEJULA (Drug) $123.87
- DISEASE STATE (Drug) $90.78
- Aliqopa (Drug) $83.88
- Venclexta (Drug) $64.31
- Avastin (Biological) $63.39
- KISQALI (Drug) $34.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Gainesville
Dr. George Kim, M.d, M.D
Medical Oncology — Payments: $1.0M
Medical Oncology $1.0M
Dr. John Wingard, Md, MD
Medical Oncology — Payments: $147,953
Medical Oncology $147,953
Christopher Cogle, Md, MD
Medical Oncology — Payments: $33,817
Medical Oncology $33,817
Andrew Johnson, M.d, M.D
Medical Oncology — Payments: $21,882
Medical Oncology $21,882
Richard Locicero, M.d, M.D
Medical Oncology — Payments: $12,834
Medical Oncology $12,834
Devi Sampat, Md, MD
Medical Oncology — Payments: $10,292
Medical Oncology $10,292